James A. Fagin

This study shows that loss of MHC Class II in BRAF-mutant anaplastic thyroid cancers leads to resistance to MAPK inhibitors by reducing CD4+ T-cell activation.

The paper develops Mosaic, a machine learning system that classifies tumors into detailed subtypes and identifies molecular phenotypes using histopathologic and genomic data from a large patient cohort.

This study shows that RBM10 loss causes aberrant splicing of cytoskeletal and ECM genes, leading to RAC1 activation and metastatic fitness in thyroid cancer.

This study identifies TET2-mutant clonal hematopoiesis in thyroid cancer microenvironments and shows that TGFβ signaling from these macrophages mediates resistance to BRAF/MEK inhibition, with TGFβ inhibition restoring sensitivity.

The paper shows oncologic therapy increases clonal hematopoiesis with DDR mutations, which predicts risk of therapy-related myeloid neoplasms.